華熙生物(688363.SH)擬2.9億元收購佛思特公司100%股權
格隆匯6月9日丨華熙生物(688363.SH)公佈,公司與東營佛思特生物工程有限公司(“佛思特公司”)管理人及東辰控股集團有限公司(“東辰集團”)於2020年6月5日簽署了《東辰集團生物醫藥板塊重整投資協議》(“重整投資協議”),約定以人民幣2.9億元收購佛思特公司100%的股權(對應佛思特公司的資產範圍為標的資產)。
佛思特公司主營透明質酸原料的生產和銷售,建設了具有國內領先水平的透明質酸系列產品生產裝置。佛思特公司生產的透明質酸原料以食品級為主,化粧品級為輔,目前透明質酸年產能100噸。此次對佛思特公司的收購,將提升公司透明質酸整體產能、豐富原料銷售區域,實現公司透明質酸業務的產業協同,進一步提高公司在行業中的市場佔有率和綜合競爭力。
此次交易完成後,佛思特公司成為公司全資子公司,在滿足合併條件後,將按照非同一控制下的企業合併納入公司報表合併範圍。佛思特公司收入、利潤規模相對較小,對公司經營性收入、利潤等財務指標無重大影響。
此次交易對價為2.9億元人民幣,公司擬通過自有資金結合外部融資的方式,按照重整投資協議的約定分期支付。公司目前生產經營狀況良好、現金流充裕,交易對價的支付對公司日常生產經營、現金流無重大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.